Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Cash from Financing Activities (2016 - 2017)

Bone Biologics (BBLG) has disclosed Cash from Financing Activities for 2 consecutive years, with $1.4 million as the latest value for Q3 2017.

  • On a quarterly basis, Cash from Financing Activities changed N/A to $1.4 million in Q3 2017 year-over-year; TTM through Dec 2017 was $3.4 million, a 50.24% decrease, with the full-year FY2025 number at $4.7 million, up 6.26% from a year prior.
  • Cash from Financing Activities was $1.4 million for Q3 2017 at Bone Biologics, down from $2.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $5.6 million in Q1 2016 to a low of $1.2 million in Q4 2016.